Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Functional Evaluation of Novel Therapeutic Targets for High-Grade Serous Ovarian Cancer

EF 2023-24

Résumé
Ovarian cancer is the fifth leading cause of cancer related death for Canadian women. The high­ grade serous (HGSC) is the most prevalent and lethal subtype, accounting for 70­% of all cases. Despite recent improvements in treatment, 75% of patients relapse with chemoresistance and die from this disease. Thus, there is a need for the discovery of novel therapeutics. Plasma membrane proteins make favourable drug targets due to their easily accessible cell surface localization and their role in important biological functions. Recently, our lab applied a N-glycoproteomic enrichment strategy, cell surface capture, to empirically define the cell surface proteomes of HGSC cell lines, normal epithelial cell lines and HGSC patient-derived cancer-associated fibroblast cell cultures. Integration with publicly available patient molecular profiling data has identified and prioritized SLC7A1 as a HGSC specific surface protein with limited expression in normal tissue and high expression in HGSC patients. As the biological role of SLC7A1 in HGSC is not well characterized, the aim of this project is to functionally evaluate and characterize SLC7A1 in HGSC-representative cell lines and xenograft models. I will use CRISPR-Cas9 mediated knockdown methods to evaluate and functionally characterize SLC7A1 in both 2D and 3D in vitro assays along with in vivo xenograft models. Ultimately, we anticipate that this project can enable the development of novel therapeutic antibodies for HGSC.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506444
Name
Lin Brian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Functional Evaluation of Novel Therapeutic Targets for High-Grade Serous Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell-Surface Proteins; Crispr; Glycoproteomics; High-Grade Serous Cancer; Ovarian Cancer; Spheroids; Therapeutic Targets; Xenografts
Abstract
Ovarian cancer is the fifth leading cause of cancer related death for Canadian women. The high­ grade serous (HGSC) is the most prevalent and lethal subtype, accounting for 70­% of all cases. Despite recent improvements in treatment, 75% of patients relapse with chemoresistance and die from this disease. Thus, there is a need for the discovery of novel therapeutics. Plasma membrane proteins make favourable drug targets due to their easily accessible cell surface localization and their role in important biological functions. Recently, our lab applied a N-glycoproteomic enrichment strategy, cell surface capture, to empirically define the cell surface proteomes of HGSC cell lines, normal epithelial cell lines and HGSC patient-derived cancer-associated fibroblast cell cultures. Integration with publicly available patient molecular profiling data has identified and prioritized SLC7A1 as a HGSC specific surface protein with limited expression in normal tissue and high expression in HGSC patients. As the biological role of SLC7A1 in HGSC is not well characterized, the aim of this project is to functionally evaluate and characterize SLC7A1 in HGSC-representative cell lines and xenograft models. I will use CRISPR-Cas9 mediated knockdown methods to evaluate and functionally characterize SLC7A1 in both 2D and 3D in vitro assays along with in vivo xenograft models. Ultimately, we anticipate that this project can enable the development of novel therapeutic antibodies for HGSC.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lin, Brian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~